Canon Medical Components U.S.A., Inc. Announces Launch of New Products in the U.S., to Be on Display at RSNA 2022

Canon Medical Components U.S.A., Inc., a subsidiary of Canon Inc., today announced new products line-up at the Radiology Society of North America (RSNA) conference and annual meeting, held November 27 through November 30 at the McCormick Place Convention Center in Chicago, Illinois (Booth # 8127, North Hall Level 3).

RSNA 2022 is a global radiology forum where the power of imaging, education and collaboration come to life.  Canon Medical Components U.S.A., Inc. is displaying a number of innovative products, some that are now available for the first time in the United States.

The CXDI-Pro series of wireless digital radiography (DR1) devices

The Canon CXDI-Pro wireless digital radiography systems are designed to support the demands of medical imaging departments for cost-effective solutions without compromise. These new wireless detectors provide features that optimize workflow and offer the high quality and reliability that you have come to expect from Canon.

The CXDI-Pro series employs the lightweight, CXDI-703C Wireless sensor unit, which weighs approximately 2.9 kg.  The new series, designed to reduce the physical burden on patients, inherits the same IP55 standard3 compliant dust and water resistance of predecessor models allowing for frequent cleaning of the imaging portion and protecting the device in operating rooms and other environments where stray droplets are common.  The device design also has fewer connection seams and visible screw heads in surfaces that come in contact with patients.

The CXDI-Elite series of wireless digital radiography (DR) devices

The CXDI-Elite series has high sensitivity, high image quality, and an ultra-lightweight, ergonomic design for ease of handling long battery life and AED4 function. This makes the CXDI-Elite the ideal digital radiography detector for mobile applications or any general x-ray need. The unique functions, Intelligent NR and Built-in AEC5 assistance expand the digital radiography possibilities.

New “Built-in AEC Assistance” technology for digital radiography (DR)

The CXDI-Elite series is Canon’s first digital X-ray imaging system to utilize Built-in AEC Assistance6 technology designed for general X-ray imaging. With this technology, the device’s X-ray image sensor allows for automatically terminated exposures without the use of an additional receptor (ion chamber, solid state paddle, etc.) This function works via both wireless and wired communication, which enables the optimization of X-ray dose without an external AEC sensor, even in free-position imaging such as bedside.7

New “Intelligent NR” technology for control software8 for CXDI series of digital radiography (DR) devices9

This Intelligent NR is new technology for DR control software that utilizes AI technology to reduce digital radiography image noise.  Intelligent NR is based on Canon’s proprietary AI technology that utilizes deep learning and has been trained using approximately 3,000 X-ray images obtained over the course of the company’s long history of developing the CXDI series of clinical imaging. Intelligent NR will provide radiologists with high-quality diagnostic images containing significantly less grainy noise with no noticeable loss of detail. This should make improved diagnosis possible for their patients. Intelligent NR makes it possible to reduce the noise content without losing the fine details of the anatomy, even in low dose regions. Intelligent NR results in an optimal diagnostic environment, especially for infants and pediatric patients where dose is a prevailing concern. But the image improvement will benefit all patients and exam types by providing superior images even in inherently noisy conditions such as the dense anatomy of the abdomen. This new technology has the potential to support better-quality diagnoses on the front line of medical treatment and make possible high-quality imaging with reduces X-ray dosages for patients.

These new products are now available through Canon Medical Components U.S.A., Inc.

For more information and the full list of product specifications, visit https://mcu.canon

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”